Cindy Bandala

Dr. Cindy Bandala

Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Ciudad de México, Mexico
orcid
God, science, and art

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2022 in Cells
Verified
Journal Article
Open access
PDF file
BFBerenice Franco-Juárez
Berenice Franco-Juárez
CCCristina Coronel-Cruz
Cristina Coronel-Cruz
BHBeatriz Hernández
Beatriz Hernández
SGSaul Gomez-Manzo
Saul Gomez-Manzo
Noemi Cardenas-RodríguezNoemi Cardenas-Rodríguez
Noemi Cardenas-Rodríguez
DODaniel Ortega-Cuellar
Daniel Ortega-Cuellar
Transcription factor EB (TFEB) is considered the master transcriptional regulator of autophagy and lysosomal biogenesis, which regulates target gene expression through binding to CLEAR motifs. TFEB dysregulation has been linked to the development of numerous pathological conditions; however, several other lines of evidence show that TFEB might be a point of convergence of diverse signaling pathways and might therefore modulate other important biological processes such as cellular senescence, DNA repair, ER stress, carbohydrates, and lipid metabolism and WNT signaling-related processes. The regulation of TFEB occurs predominantly at the post-translational level, including phosphorylation, acetylation, SUMOylating, PARsylation, and glycosylation. It is noteworthy that TFEB activation is context-dependent; therefore, its regulation is subjected to coordinated mechanisms that respond not only to nutrient fluctuations but also to stress cell programs to ensure proper cell homeostasis and organismal health. In this review, we provide updated insights into novel post-translational modifications that regulate TFEB activity and give an overview of TFEB beyond its widely known role in autophagy and the lysosomal pathway, thus opening the possibility of considering TFEB as a potential therapeutic target.

30 January 2018 in Current Neuropharmacology
Verified
Journal Article
Open access
PDF file
JCJose Luis Cortes-Altamirano
Jose Luis Cortes-Altamirano
Adriana OlmosAdriana Olmos
Adriana Olmos
HJHerlinda Bonilla Jaime
Herlinda Bonilla Jaime
PCPaul Carrillo-Mora
Paul Carrillo-Mora
Cindy BandalaCindy Bandala
Cindy Bandala
AAAlfonso Alfaro-Rodriguez
Alfonso Alfaro-Rodriguez
Background: The aim of this review was to identify the mechanisms by which serotonin receptors involved at the central level are able to modulate the nociceptive response. Pain is a defense mechanism of the body that entails physiological, anatomical, neurochemical, and psychological changes, and is defined as an unpleasant sensory and emotional experience with potential risk of tissue damage, comprising the leading cause of appointments with Physicians worldwide. Treatment for this symptom has generated several neuropharmacological lines of research, due to the different types of pain and the various drugs employed to treat this condition. Serotonin [5-HydroxyTryptamine (5-HT)] is a neurotransmitter with seven families (5-HT1–5-HT7) and approximately 15 receptor subtypes. Serotonin modulates neuronal activity; however, this neurotransmitter is related with a number of physiological processes, such as cardiovascular function, gastric motility, renal function, etc. On the other hand, several researches reported that serotonin modulates nociceptive response through 5-HT1, 5-HT2, 5-HT3, and 5-HT7 receptors in the Central Nervous System (CNS). Method: In this review, a search was conducted on PubMed, ProQuest, EBSCO, and the Science Citation Index for studies evaluating the effects of 5-HT1, 5-HT2, 5-HT3, and 5-HT7 receptors in the CNS on the modulation of different types of pain. Conclusions We concluded that 5-HT1, 5-HT2, 5-HT3, and 5-HT7 receptors in the CNS modulate the pain, but this depends on the distribution of the receptors, dose of agonists or antagonists, administration route, pain type and duration to order to inhibit, to excite, or even maintain the nociceptive response.

13 April 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ICItzel Jatziri Contreras
Itzel Jatziri Contreras
Noemi Cardenas-RodríguezNoemi Cardenas-Rodríguez
Noemi Cardenas-Rodríguez
Antonio Romo-MancillasAntonio Romo-Mancillas
Antonio Romo-Mancillas
Cindy BandalaCindy Bandala
Cindy Bandala
SZSergio R Zamudio
Sergio R Zamudio
LMLuz Adriana Pichardo- Macías
Luz Adriana Pichardo- Macías
Epilepsy is a chronic disease that affects millions of people worldwide. Antiepileptic drugs (AEDs) are used to control seizures. Even though parts of their mechanisms of action are known, there are still components that need to be studied. Therefore, the search for novel drugs, new molecular targets, and a better understanding of the mechanisms of action of existing drugs is still crucial. Levetiracetam (LEV) is an AED that has been shown to be effective in seizure control and is well-tolerable, with a novel mechanism of action through an interaction with the synaptic vesicle protein 2A (SV2A). Moreover, LEV has other molecular targets that involve calcium homeostasis, the GABAergic system, and AMPA receptors among others, that might be integrated into a single mechanism of action that could explain the antiepileptogenic, anti-inflammatory, neuroprotective, and antioxidant properties of LEV. This puts it as a possible multitarget drug with clinical applications other than for epilepsy. According to the above, the objective of this work was to carry out a comprehensive and integrative review of LEV in relation to its clinical uses, structural properties, therapeutical targets, and different molecular, genetic, and systemic action mechanisms in order to consider LEV as a candidate for drug repurposing.

Verified
Journal Article
Open access
PDF file
Noemi Cardenas-RodríguezNoemi Cardenas-Rodríguez
Noemi Cardenas-Rodríguez
BHBernardino Huerta-Gertrudis
Bernardino Huerta-Gertrudis
LRLiliana Rivera-Espinosa
Liliana Rivera-Espinosa
HCHortencia Montesinos Correa
Hortencia Montesinos Correa
Cindy BandalaCindy Bandala
Cindy Bandala
ECElvia Coballase
Elvia Coballase
Oxidative stress, a state of imbalance in the production of reactive oxygen species and nitrogen, is induced by a wide variety of factors. This biochemical state is associated with systemic diseases, and diseases affecting the central nervous system. Epilepsy is a chronic neurological disorder with refractoriness to drug therapy at about 30%. Currently, experimental evidence supports the involvement of oxidative stress in seizures, in the process of their generation, and in the mechanisms associated with refractoriness to drug therapy. Hence, the aim of this review is to present information in order to facilitate the handling of this evidence and determine the therapeutic impact of the biochemical status for this pathology.

28 February 2013 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
Cindy BandalaCindy Bandala
Cindy Bandala
Martin Perez-SantosMartin Perez-Santos
Martin Perez-Santos
ELEleazar Lara-Padilla
Eleazar Lara-Padilla
MLMa. Guadalupe Delgado Lopez
Ma. Guadalupe Delgado Lopez
MAMaricruz Anaya-Ruiz
Maricruz Anaya-Ruiz
The present study was performed to assess the activity of the botulinum toxin A on breast cancer cells. The T47D cell line was exposed to diverse concentrations of the botulinum toxin A and cell viability and apoptosis were estimated using MTT and propidium iodine/annexin V methods, respectively. Botulinum toxin A exerted greater cytotoxic activity in T47D cells in comparison with MCF10A normal cells; this appeared to be via apoptotic processes caspase-3 and -7. In conclusion, botulinum toxin A induces caspase-3 and -7 dependent apoptotic processes in the T47D breast cancer cell line.

26 January 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HGHéctor Guerrero-Flores
Héctor Guerrero-Flores
TATeresa Apresa-García
Teresa Apresa-García
ÓGÓnix Garay-Villar
Ónix Garay-Villar
ASAlejandro Sánchez-Pérez
Alejandro Sánchez-Pérez
DFDavid Flores-Villegas
David Flores-Villegas
MSMauricio Salcedo
Mauricio Salcedo
Cervical Cancer (CC) has become a public health concern of alarming proportions in many developing countries such as Mexico, particularly in low income sectors and marginalized regions. As such, an early detection is a key medical factor in improving not only their population’s quality of life but also its life expectancy. Interestingly, there has been an increase in the number of reports describing successful attempts at detecting cancer cells in human tissues or fluids using trained (sniffer) dogs. The great odor detection threshold exhibited by dogs is not unheard of. However, this represented a potential opportunity to develop an affordable, accessible, and non-invasive method for detection of CC. Using clicker training, a male beagle was trained to recognize CC odor. During training, fresh CC biopsies were used as a reference point. Other samples used included cervical smears on glass slides and medical surgical bandages used as intimate sanitary pads by CC patients. A double-blind procedure was exercised when testing the beagle’s ability to discriminate CC from control samples. The beagle was proven able to detect CC-specific volatile organic compounds (VOC) contained in both fresh cervical smear samples and adsorbent material samples. Beagle’s success rate at detecting and discriminating CC and non-CC odors, as indicated by specificity and sensitivity values recorded during the experiment, stood at an overall high (>90%). CC-related VOC in adsorbent materials were detectable after only eight hours of use by CC patients. Present data suggests different applications for VOC from the uterine cervix to be used in the detection and diagnosis of CC. Furthermore, data supports the use of trained dogs as a viable, affordable, non-invasive and, therefore, highly relevant alternative method for detection of CC lesions. Additional benefits of this method include its quick turnaround time and ease of use while remaining highly accurate and robust.